Showing 19,681 - 19,700 results of 24,549 for search '(( significant decrease decrease ) OR ( significantly ((greater increase) OR (a decrease)) ))', query time: 0.58s Refine Results
  1. 19681

    HIF-1α is the signal downstream of ROS-RET. by Daniel Sobrido-Cameán (5049743)

    Published 2025
    “…<b>(B)</b> HIF-1α is stabilized and translocated to nucleus in muscles following 32°C or increase ROS by mitochondrial Complex-I (Ndi1 mis-expression) during the critical period. …”
  2. 19682

    Table 1_Mangiferin mitigates neurological deficits and ferroptosis via NRF2/ARE pathway activation in cerebral ischemia-reperfusion rats.xlsx by Chenjia Peng (21404753)

    Published 2025
    “…Ferroptosis in stroke rats was significantly inhibited by MGF. MGF significantly increased the expression of NRF2, FTL, SLC7A11 and GPX4. …”
  3. 19683

    Table 4_Mangiferin mitigates neurological deficits and ferroptosis via NRF2/ARE pathway activation in cerebral ischemia-reperfusion rats.xlsx by Chenjia Peng (21404753)

    Published 2025
    “…Ferroptosis in stroke rats was significantly inhibited by MGF. MGF significantly increased the expression of NRF2, FTL, SLC7A11 and GPX4. …”
  4. 19684

    Table 2_Mangiferin mitigates neurological deficits and ferroptosis via NRF2/ARE pathway activation in cerebral ischemia-reperfusion rats.xlsx by Chenjia Peng (21404753)

    Published 2025
    “…Ferroptosis in stroke rats was significantly inhibited by MGF. MGF significantly increased the expression of NRF2, FTL, SLC7A11 and GPX4. …”
  5. 19685

    Table 3_Mangiferin mitigates neurological deficits and ferroptosis via NRF2/ARE pathway activation in cerebral ischemia-reperfusion rats.xlsx by Chenjia Peng (21404753)

    Published 2025
    “…Ferroptosis in stroke rats was significantly inhibited by MGF. MGF significantly increased the expression of NRF2, FTL, SLC7A11 and GPX4. …”
  6. 19686

    Table 1_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  7. 19687

    Table 5_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  8. 19688

    Table 4_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  9. 19689

    Table 2_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  10. 19690

    Table 3_The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: ev... by Juyi Li (8996117)

    Published 2025
    “…Elevated NHHR levels in the Q2 and Q3 groups remained significantly linked to a decreased risk of advanced liver fibrosis, with odds ratios of 0.61 (95% CI 0.40–0.94, P = 0.03) and 0.64 (95% CI 0.47–0.89, P = 0.01), respectively. …”
  11. 19691

    Data_Sheet_5_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.xlsx by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  12. 19692

    Data_Sheet_3_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.xlsx by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  13. 19693

    Data_Sheet_2_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.xlsx by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  14. 19694

    Table_1_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.DOCX by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  15. 19695

    Data_Sheet_1_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.xlsx by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  16. 19696

    Image_1_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.tif by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  17. 19697

    Data_Sheet_4_Clonal and resistance profiles of fluoroquinolone-resistant uropathogenic Escherichia coli in countries with different practices of antibiotic prescription.xlsx by Debarati Choudhury (687979)

    Published 2024
    “…Increased 3GC resistance in Iraqi strains was linked to a higher proportion of bla<sub>CTX-M-15</sub>-carrying H30Rx subclade isolates. …”
  18. 19698

    Data and R scripts for: Plant species diversity and dominant plant functional types control productivity in a reclaimed mineland prairie by G. Matt Davies (11028363)

    Published 2025
    “…Prairie biomass was significantly greater in seed-mixes containing big bluestem (<i>Andropogon gerardii</i>) and was also significantly related to Shannon diversity. …”
  19. 19699

    Table 4_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  20. 19700

    Data Sheet 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.doc by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”